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ABSTRACT 
 
Focus of this study was on the development of one of the faster, simpler, cost effective and 
environmentally friendly sample pre-treatment techniques which employs a supported liquid 
membrane, in this case a Hollow-fiber supported liquid membrane (HF-SLM) for determination 
of seven (7) quinolone antibiotics (enrofloxacin, ciprofloxacin, danofloxacin, difloxacin, 
norfloxacin, nalidixic acid and sarafloxacin) in bovine kidney samples followed by LC-MS/MS 
analysis.  The key parameters of the method were optimized and the method was validated 
following the 2002/657 EC guidelines.  The optimum HF-SLM conditions were therefore; 
NaH2PO4 as a donor phase at pH 7, 0.1% formic acid at pH 3 as acceptor phase.  Triethylamine 
was the optimized liquid membrane and the stirring time was optimized at 1 hour.  Separation of 
the 7 quinolones including 3 internal standards (enrofloxacin-d5, norfloxacin-d5 and difloxacin-d3) 
was carried out on a Phenomenex Kinetex 2.6 μm XB-C18, 100 mm x 4.6 mm, 100Å column.  
Validation parameters such as Correlation coefficients (r2) ranging from 0.9714-0.9975 were 
obtained, while limit of detection (LOD) ranged between 3-39 ug kg-1 and limit of quantification 
(LOQ) ranged between 10-130 ug kg-1.  The obtained limits at which it can be concluded with an 
error probability of α = 95% that a sample is non-compliant (CCα) ranged from 28 – 422 ug kg-1 
while CCβ; the smallest content of the substance that may be detected, identified or quantified in 
a sample with an error probability of  β = 95%,  ranged from 29 – 454 ug kg-1.  The method was 
found to be reproducible with CVs ≤ 23 %.  The tested samples from Botswana local abattoirs 
showed no presence of quinolone antibiotics when the method was applied to real bovine kidney 
samples.  Hollow-fiber supported liquid membrane can therefore be used for extraction of 
biological samples since it is a “greener technique” which uses less solvent which are less harmful 
to the environment when disposed as compared to dispersive Solid Phase Extraction (dSPE). 
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CHAPTER 1: INTRODUCTION 
1.1 Background 
 
The food safety aspect is growing globally hence the need to monitor drugs in food from animal and 
animal products is necessary.  Veterinary drugs are widely used in human and veterinary medicine for 
the treatment, control and prevention of bacterial diseases.  Some of these drugs are very good for the 
treatment of infections in humans [1].  Examples of classes of veterinary drugs include 
chloramphenicol, beta-agonists, ivermectins, tetracyclines, β-lactams, aminoglycosides, macrolides, 
coccidiostats, sulfonamides, lincosamides and quinolones.  Quinolone antibiotics are one of the 
veterinary drugs used in reared animals for treatment of diseases by farmers.  They are also added to 
animal feeds [2] to be used as growth promoters and to increase animal mass [3-8]. 
 
Authorities in many countries worldwide are mandated with raising consumer awareness on food 
safety and the increasing antimicrobial resistance due to the discovery of new resistant strains of 
bacteria and others that are increasing over time.  As a result there is increasing pressure on food safety 
laboratories to monitor the use of these drugs and ensure the safety of food for human consumption 
[9], hence the establishment of Maximum Residue Limits (MRLs) of compounds legally permitted in 
foodstuffs entering the human food chain as stipulated by the Food and Agriculture Organisation of 
the United Nations (FAO), European Union (EU), Health Canada, Japan, Food and Drug 
Administration (FDA) and Unites States Environmental Protection Agency (USEPA).  These bodies 
are mandated with protecting and promoting public health and or the environment by enforcing the 
laws, directives and regulations related to their various objectives which include among others 
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production, distribution, importation, sale and/or use of consumer products, pest control products, 
drugs, medical devices and natural health products.   The European Union’s commission regulation 
EC No 1181/2002 [10] and commission regulation (EU) No 37/2010 [11] for example, are such 
instruments that have been put into place to monitor the level of these drugs in food.  The directives 
are a guide to member countries as well as exporting countries, such as Botswana which exports beef 
to the EU.  Council directive 96/23/EC [12] is the legislation regarding the control of antibiotic residues 
in live animals and animal products.  Commission Decision 2002/657/EC [13] describe in detail the 
preferred analytical methods such as HPLC, LC-MS/MS, AAS, ICP-MS etc, and their performance 
criteria.  According to Council directive 96/23/EC, residues are divided into two groups, which are; A 
and B for the purposes of monitoring and defining the legislation relating to them [14].  Group A refers 
to substances having an anabolic effect and are not authorized to be used while group B refers to 
veterinary drugs and environmental contaminants [12] such as pesticides and heavy metals.  According 
to this classification, the groups to be monitored are as shown in Table 1.1; classification of veterinary 
drugs according to group A and B.  Quinolones belong to group B1 of antimicrobials as shown in 
italics. 
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Table 1.1: Classification of veterinary drugs according to group A and B [14] 
NAME OF GROUP NAME OF GROUP 
A1 Stilbenes B1  ANTIMICROBIALS 
Penicillins 
Quinolones 
Lincosamides 
Sulphonamides 
Tetracyclines 
Aminoglycosides 
Cephalosporins 
Macrolides 
A2 Thyrostats B2a Anthelmentics & 
Avermectins 
B2b Anticoccidials 
B2c Carbamates & 
Pyrethroids 
B2d Sedatives 
B2e Non-Steroidal anti-
inflammatory drugs 
B2f Glucocorticoids 
A3 Steroids B3a & b Organochlorinated 
Pesticides, PCBs and  
4 
 
NAME OF GROUP NAME OF GROUP 
   Organophosphorus 
pesticides 
A4 Resorcyclic acid lactones B3c Heavy metals  
A5 Beta agonists B3d Mycotoxins 
A6 Chloramphenicol + Nitroimidazoles 
+ Nitrofurans 
  
 
 
Considerable research has been carried out on determination of quinolones in various matrices, using 
different extraction techniques and analysis methods.  Traditional extraction techniques previously 
explored included liquid-liquid extraction and solid phase extraction to name a few.  The recent trend 
is to develop miniaturized and greener sample-preparation methods which use lower quantities of 
solvents are environmentally friendly, faster, easy to use, inexpensive and compatible with a wide 
range of analytical instruments [15, 16, 17].  These techniques are termed liquid-phase microextraction 
(LPME), examples of which are single-drop microextraction (SDME), dispersive liquid–liquid 
microextraction (DLLME) and hollow-fiber supported liquid membrane (HF-SLM). 
 
This current study explores the determination of quinolone antibiotics in bovine kidney using hollow-
fiber-supported liquid membrane (HF-SLM) followed by liquid chromatography mass spectrometry.  
To date we are not aware of any work published before on HF-SLM in biological samples such as 
kidney, liver or muscle, and this has been found to be a research area of interest. 
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1.2 Problem statement 
 
Since its development, work on HF-SLM by various researchers has been on determination of 
veterinary drugs in wastewater and biological samples such as urine and none has been done on meat 
samples.  This research is focused on development of HF-SLM as a sample preparation and/or clean-
up for biological samples such as meat, kidney and liver.  In addition challenges involved when using 
HF-SLM in kidney samples were considered. 
 
1.3 Rationale 
 
The importance of this study is to move away from conventional extraction methods specifically solid 
phase extraction and liquid-liquid extraction which uses large amounts of solvents posing a challenge 
to the environment due to the difficulty and expenses related to disposal.  The study proposes a greener 
technique such as hollow fiber-supported liquid microextraction which affords comparable extraction 
efficiencies and clean samples, faster and also in an environmentally friendly way. 
 
1.4 Aims and objectives 
The aim of this study is to develop a greener sample preparation method for detecting and quantifying 
quinolone antibiotics in bovine kidney samples using HF-SLM followed by LC-MS/MS analysis.  This 
was achieved through the following specific objectives; 
 To develop an LC-ESI-MS/MS separation method for quinolones in bovine kidney samples, 
6 
 
 To validate the separation method based on the following validation parameters: (a) Linearity; 
(b) Precision; (c) Limit of detection (LOD) and (d) Limit of quantification (LOQ). 
 To develop and optimise two sample extraction methods (i) hollow fiber – supported liquid 
membrane (HF-SLM) and (ii) dispersive solid phase extraction (dSPE). 
 To validate HF-SLM and dSPE methods according to Commission Decision 2002/657 EC.  
 To compare the performance merits between HF-SLM and dSPE. 
  To apply the developed HF-SLM method to real bovine kidney samples. 
 
1.5 Dissertation Overview 
 
This dissertation is made of five chapters; Chapter 1 introduces the work and the objectives to be 
attained from the research work while Chapter 2 covers the literature review of the main research 
topic of quinolones and their extraction from biological samples using a “greener technique”.  It also 
covers comparison of different extraction techniques and the analytical methods of analysis.  The  
Experimental procedures used in the study are covered in Chapter 3.   
Chapter 4 shows the results obtained from the experiments conducted when extracting samples using 
the Hollow fiber- supported liquid membrane compared to those obtained through dispersive solid 
phase extraction. Chapter 5 presents conclusions of the research undertaken and recommendations for 
future work. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Introduction 
 
Quinolones are a family of synthetic broad-spectrum antibiotics [18].  Nalidixic acid was the first 
quinolone antibiotic to be discovered in the early 1960s.  Development of other compounds such as 
flumequine, norfloxacin and enoxacin was seen after a decade and became available for clinical use [19].   
The structures of these molecules are based or derived from the heterobicyclic aromatic compound called 
quinoline (Figure 2.1), the name of which originated from the oily substance obtained after the alkaline 
distillation of quinine [19, 20].  A wide variety of quinolone compounds are a product of animals, plants 
and microorganisms reported to have been discovered from the formation of quinine compound [21].  
The basic structure of the fluoroquinolone class is therefore based upon the quinoline ring system [22, 
23].  Many researchers have developed wide interest (scientifically and clinically) around these analytes 
since their discovery [22].  In addition to their uses in animal husbandry, they are also used in human 
pharmaceuticals for treatment of urinary tract infections [19, 24]. 
 
   
Figure 2.1:  Structure of quinoline, shown with its accepted numbering scheme to indicate sites of 
substitution [22, 23]. 
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2.2 Chemistry of quinolones 
 
Most quinolones belong to the subset fluoroquinolones, due to the fluorine atom attached to the central 
ring system, normally attached at Carbon 6 or 7 positions as shown in Figure 2.2.  The blue substituted 
R in most cases is a piperazine; the compound becomes a fluoroquinolone if the connection shown in 
red is fluorine.  This basic fluoroquinolone molecule was also studied by Andersson and MacGowan 
[19, 22, 25].  They stated that “one of the earliest changes to the structure was addition of a fluorine 
molecule at position 6” [19, 26].  The single alteration provides a more than 10-fold increase in gyrase 
inhibition and up to 100-fold improvement in minimum inhibitory concentration (MIC) [27].  This 
inhibition was also studied by Sarkozy [28].  The development of the two major groups of quinolones 
and naphthyridones were reported by Domagala (1994).  They discovered that the presence of nitrogen 
at position 8 identifies another group termed naphthyridones, example of which is nalidixic acid.  A 
carbon and associated group at position 8 identifies the quinolones, as reported in a paper by Ball 
(2000) [19, 29].  The structures of these two groups (quinolones and naphthyridones) were reported to 
have been further enhanced by the addition of groups to the N1, C-5 and C-7 positions of their 
respective basic molecules.  The discovery continues to suggest that “the addition of piperazine to the 
C-7 position has effectively improved   activity against Gram-negative organisms.  This is well 
illustrated in the structure for norfloxacin”.  New research suggests that a piperazine ring may play a 
role in inhibiting efflux mechanisms, thereby improving the potency of these drugs.  The structure of 
norfloxacin is a good example to illustrate these developments and is extended to all quinolones (except 
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garenoxacin) which has fluorine at position 6 while other analytes have six-membered rings at position 
C-7 [19].  
 
                           
Figure 2.2:   Basic structure of quinolones  
 
2.3 Generations of Quinolones 
 
Quinolones are divided into generations according to their antibacterial performance [29].  There are 
four generations though the first generation is rarely used nowadays.  Some quinolones from the second, 
third, and fourth generation drugs are reported to have been removed from clinical practice due to severe 
toxicity issues or discontinued by their manufacturers.  The generations are as follows; 
 
1. First generation agents; these are compounds reported to have had false antimicrobial activity as a 
result of the addition of a piperazine substituent at position 7 of the naphthyridone core [29].  
2. Second generation agents have replaced the first generation and predominantly have Gram-
negative activity.  The next significant step was seen with formation of generation IIb, with 
improved Gram-positive activity [30].  Examples of the first and second generations agents are as 
summarized in the table below. 
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Table 2.1:  First and second generations agents 
FIRST GENERATION SECOND GENERATION 
Cinoxacin Ciprofloxacin 
Flumequine Enrofloxacin [31] 
Nalidixic acid Sarafloxacin [31] 
Oxolinic acid Difloxacin [31] 
Pipemidic acid Enoxacin 
 Norfloxacin 
 Lomefloxacin  
 
3. Temafloxacin and sparfloxacin forms the third generation agents which are characteristic of having 
enhanced activity against Gram-positive pathogens [29]. 
4. The last generation, which is called fourth generation agents, is made of clinafloxacin and 
gatifloxacin.  
 
Quinolone antibacterial agents are compounds which pose both negative and positive moieties and are 
termed amphoteric and are considered zwitterionic.  Their pKa is between acidic and basic due to the 
carboxylic acid and one or more amine (which are basic) functional groups attached to the aromatic 
structures [28, 32].  The behaviour of quinolones is compared to 1-naphthoic acid due to their structural 
similarity.  1-naphthoic acid is reported to have one pKa of 3.69 which corresponds to the carboxylic 
group attached to the benzene ring of the quinolones structure.  Due to these reason, pKa, 1   of 
flouroquinolones was assigned to the carboxylic acid [33].  The remaining pKa’s values were assigned 
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to the three nitrogen sites based on their electron density which increases from moieties B, C to D.  
Therefore pKa, 2 was assigned to moiety B, pKa, 3 to C and pKa, 4 to D as reported by Buckingham et al.   
[34].  Figure 2.3 illustrates the pKa’s corresponding to the moieties.  Table 2.2 shows the 
physicochemical properties of the nine quinolones including three internal standards studied in this work.  
 
 
Figure 2.3: Moieties corresponding to the pKa values [34]. 
 
2.4 Uses of quinolones 
 
Studies have shown that quinolones act by not allowing for duplication and unwinding of bacterial DNA 
[35].  Ronald and Low (2003) also made a discovery which stated that “quinolones in food of animal 
origin lead to the development of resistance against the quinolone bacteria.  These bacteria are 
transmitted to humans through direct contact with the animal or when consuming food and water 
contaminated with these drugs.  An example of resistance to quinolones which is reported to have been 
observed since the early 1990s is the transmission of the most common and dangerous bacteria called 
campylobacter which is transmitted from animal-to-human.  This was also reported in a paper by Zhao 
and Stevens, Agilent applications note [18, 36]. 
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Use of quinolones in livestock has been identified as a particular area of concern because of their 
significance in treatment of a broad range of infections in humans including gastrointestinal infections 
caused by zoonotic bacteria transmitted to humans via the food chain.  Nalidixic acid was the first 
quinolone used clinically in animals.  Subsequent quinolones, all congeners of nalidixic acid 
synthesised in the late 1960s and 1970s, clearly showed both improved antibacterial and 
pharmacokinetic properties as well as reduced side effects.  Some of these are, for example, flumequine 
and oxolinic acid which are still used in veterinary medicine in a limited number of countries.  
Clinically, a significant breakthrough was achieved by the introduction of the fluoroquinolones which 
are available for therapy of animals in worldwide.  However, the usage of these fluoroquinolones 
differs greatly from species-to-species, their occurrence and locations [3]. 
 
2.5 Limitations and/or challenges 
 
Abuse and misuse of veterinary drugs and non-compliance to withdrawal periods during administration 
to animals can leave some residues of these drugs in edible animal tissues, affecting people’s health.  
These can lead to a health scare due to possible toxic effects, development of resistance to medicines, 
allergies, etc. as well as environmental and industrial problems [3-6, 37-40].  The health problems of 
toxic effects and quinolone-resistance mentioned above are the effects of these drug residues and/or their 
metabolites in meat and meat products [41].  Abuse and misuse of veterinary drugs greatly affects 
international trade of food products [42].  The effect on the country’s trade market due to their food 
products testing positive to some of these drugs could be irreparable especially to emerging economies.  
Monitoring of these antibiotics in food is therefore very vital.  
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Table 2.2:  Physicochemical properties and structures of quinolones 
 
Compound name/structure MW 
(g mol-1) 
CAS No. pKa [43] MRL (µg kg-1) in 
bovine kidney 
[11] 
Enrofloxacin 
 
359.4 93106-06-6 
 
 
 
 
 
3.85±0.30; 6.19±0.18 200 
Ciprofloxacin 
 
331. 3 85721-33-1 
 
 
 
 
 
3.01±0.30; 6.14±0.13; 
8.70±0.09; 
10.58±0.30 
200 
Difloxacin 
 
399.4 98106-17-3 
 
 
 
 
5.66±0.04; 7.24±0.06 800 
Sarafloxacin 
 
 
 
385.4 98105-99-8 6.00; 8.6 200 
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Compound name/structure MW 
(g mol-1) 
CAS No. pKa [43] MRL (µg kg-1) in 
bovine kidney 
[11] 
Norfloxacin 
 
319.3 70458-96-7 6.22, 8.38 100 
Nalidixic acid 
 
232.2 389-08-2 5.95 100 
Danofloxacin 
 
357.4 112398-08-
0 
6.07±0.06, 8.56±0.07 400 
Enrofloxacin-d5 
 
 
364.4 1173021-
92-5 
 Internal standard 
(IS) 
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Compound name/structure MW 
(g mol-1) 
CAS No. pKa [43] MRL (µg kg-1) in 
bovine kidney 
[11] 
Norfloxacin-d5 
 
324 1015856-
57-1 
 Internal standard 
(IS) 
Difloxacin-d3 
 
403 1173021-
89-0     
 Internal standard 
(IS) 
 
 
2.6 Sample extraction methods for quinolones 
 
Sample preparation is a very important part of analytical procedures and it has been reported to be time 
consuming and not cost effective [44].  It is a pre-requisite to any analytical method since it has been 
discovered that analysis of pure samples which has not been extracted or treated can harm the 
equipment [15].  Sample preparation involves pre-treatment which includes isolation, clean-up and/or 
pre-concentration of the analyte.  The basic concept of sample-preparation methods is to convert a real 
matrix into a sample suitable for analysis [45].  Various traditional sample preparation methods such 
as liquid liquid extraction (LLE), solid phase extraction (SPE), Soxhlet extraction [46], automated 
microdialysis [47] and automated extraction by turbulent flow chromatography [48] have been applied 
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before for determination of quinolones.  SPE has been applied by various authors for analysis of 
quinolones in various matrices [16, 39, 49-54].  Liquid-liquid extraction has also been applied for 
extraction of quinolones from poultry muscle [52, 54].  The conventional sample-preparation 
techniques (LLE, SPE, Soxhlet, etc.) mentioned above have been found to have drawbacks such as 
complications during disposal, time-consuming and labour intensive; requirement of large amounts of  
organic solvents which are toxic to the environment during disposal and carcinogenic.   
 
Usage of large volumes of solvents which are harmful to the environmental as well as expensive to 
dispose are slowly being minimized and replaced with environmental friendly solvents where possible 
[15].  This has led to a pressure to develop sample preparation methods which are fast, precise, accurate 
and sensitive [15].  As presently discovered, the main aim is to change to simplified and miniaturized 
sample preparation techniques and decreasing the quantities of environmentally unfriendly organic 
solvents used [15, 16, 17].  The principles of green chemistry, introduced by Anastas and Warner are 
directly related to analytical chemistry.  They stated that “the most important green chemistry principle 
is; to prevent generation of waste, use of safer solvents and auxiliaries and design for energy 
efficiency” [55].  Simple, inexpensive sample preparation methods that use minimal solvents such as 
liquid-phase microextraction (LPME) have been introduced recently.  LPME is a technique which uses 
less amount of solvent for sample pre-treatment as compared to LLE.  Small microliter volumes of 
solvent are required to concentrate analytes from various samples rather than hundreds of millilitres 
needed in traditional LLE.  It is compatible with gas chromatography (GC), capillary electrophoresis 
(CE) and HPLC.   
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In LPME, extraction takes place from an aqueous sample containing analytes termed THE donor phase 
into a small amount of a water-immiscible solvent termed THE acceptor phase.  The three main 
categories of LPME are: (i) single-drop microextraction (SDME), (ii) dispersive liquid–liquid 
microextraction (DLLME) and (iii) hollow-fiber microextraction (HF-LPME) [15].  HF-LPME was 
introduced by Pedersen-Bjergaard and Rasmussen [56] using the basic principle of supported liquid 
membrane (SLM).  The supported liquid membrane was developed by Audunsson as a sample clean-
up and/or pre-concentration of amines in a flow system [57].  The principle of SLM was developed by 
the Lund research group in Sweden following the publication by Audunsson.  Various authors have 
applied supported liquid membrane as published in various research papers [58-62].  A membrane is 
defined as a semi-permeable barrier between two phases.  Considering membranes as phase separators, 
this concept can be extended to liquids as well.  A liquid that is immiscible with the donor phase and 
receiving phase solutions and serves as a semi-permeable barrier between these two liquid phases is 
called a liquid membrane [63, 64].  Liquid membrane based extraction is a combination of liquid-liquid 
extraction and membrane separation in a single device.   
 
Liquid membrane extraction is divided into three-phase systems and two phase systems.  Supported 
liquid membrane (SLM), is a membrane extraction based on a three-phase system whereby a thin film 
of an organic phase is immobilised in a hydrophobic porous polymer membrane, which is placed 
between two aqueous liquids (the donor and the acceptor solutions) [45].  This technique allows for 
the extraction and pre-concentration of ionisable analytes by an appropriate pH adjustment of both the 
sample (donor solution) and the extractant phase (acceptor solution) [16].  Phosphate buffers or alkalis 
are more preferred for extraction of analytes from sample matrix instead of organic solvents [23].  The 
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pH of the buffer containing the extracted sample is adjusted in such a way that the analytes are in their 
neutral form in the donor solution [16].  This principle is suitable for the extraction of polar compounds 
which are acidic or basic, charged, metals and it is compatible with reversed phase HPLC [65].  To 
extract basic compounds, it is important to adjust the pH of the sample to alkalinity such that solubility 
of the analytes is suppressed while pH in the acceptor solution should be low in order to promote 
analyte solubility.  This set-up allows for easy extraction of basic compounds from the donor solution 
through the membrane solvent and further into the acceptor phase without being extracted back to the 
membrane solvent again [15].  By contrast, for acidic analytes pH in the sample should be low and an 
alkaline acceptor solution should be added inside the lumen of the fiber to enhance extraction in the 
same manner as for basic compounds [15].   
 
The two-phase system (aq/org), also called microporous membrane-liquid liquid extraction (MMLLE) 
is a technique where analytes are extracted into an organic solvent separated from the aqueous sample 
by a hydrophobic porous membrane.  This approach is suitable for more hydrophobic analytes and is 
compatible with gas chromatography [66].  Msagati and co-workers studied sample preparation using 
supported liquid membrane extraction techniques [67].  Msagati and Nindi applied supported liquid 
membrane as a sample preparation method for various veterinary drugs such as benzimidazole 
anthelmentics, sulphonamides, macrolides, aminoglycosides, anabolic steroids and stilbenes in various 
matrices [68-74]. 
 
The principle of HF-LPME and HF-SLM has been reported to be similar.  A measured piece of a 
porous hollow fiber (HF) used for extraction can be a rod configuration with one end closed at the 
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bottom (Figure 2.4a).  Other possible configurations observed are the u-shape or loop configuration 
where both ends are connected to guiding tubes (Figure 2.4b).  Alternatively, the hollow fiber can be 
attached directly to the needle of a microsyringe for easy injection and withdrawal of the acceptor 
solution, as illustrated in Figure 2.4c [75].  These fibers are then immersed in a sample bottle containing 
an aqueous sample solution. 
 
 
Figure 2.4:  Connection configurations; a) rod configuration, b) u-shaped or loop configuration, 
c) hollow fiber attached directly to the needle of a microsyringe [75]. 
 
To prepare the fibers for extraction, they are first dipped in the organic solvent which acts as a 
supported liquid membrane, for a few minutes to immobilize solvent in the pores, and excess solvent 
washed off with water [76].  This is followed by filling the fiber with acceptor phase using a syringe.  
The organic (membrane) solvent plays a dominant role in three phase LPME affecting both recoveries 
and extraction kinetics [77].  The main property of the solvent used as a membrane solvent is that it 
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should be immiscible with water and less polar to ensure that it remains within the pores of the fiber 
during the extraction without leaking into the aqueous sample.  It should also be of low volatility to 
prevent it from evaporating and causing leakage as well; lastly it should be of low viscosity to ensure 
increased flow of analytes in the same direction, termed “rapid mass transfer” [77].  Having met all 
the properties mentioned, the organic solvent is expected to form a thin layer within the wall of the 
HF.  It is also very important that the extraction solvent also called acceptor solution be compatible 
with the HF to ensure complete filling of the walls of the HF.  The acceptor solution is then injected 
inside the lumen of the HF.  The organic solvent that has been used as the membrane solvent can be 
used as an acceptor solution as well; in that case the extraction is called a two-phase system. The 
acceptor solution may be an acidic or alkaline aqueous solution depending on the polarity of analytes 
being extracted, resulting in a three-phase extraction system [76].   
 
To describe extraction in the two-phase LPME system, the target analytes are extracted from the 
aqueous sample and into the organic solvent (acceptor solution) present both in the porous wall and 
inside the lumen of the HF [15, 78].  Solvents which can be used as supported liquid membranes are 
normally the long chain hydrocarbons like n-undecane or kerosene and more polar compounds like di-
hexyl ether, di-octyl phosphate, [66] triethylamine and diethyl ether.   
 
Hollow fibers are made of polypropylene and are manufactured in different sizes with most common 
diameters of 600 μm or 300 μm.  All different kinds of hollow fibers reported by different authors are 
based on the Accurel®PP fiber materials produced by the company Membrana GmbH (Wuppertal, 
Germany) [66, 79-81].   
21 
 
The major advantages of HF-LPME can be summarized as follows:  
 High enrichment (up to 25,000-fold) [77] 
 Excellent sample clean-up  
 Direct compatibility with HPLC, CE and MS 
 Low solvent consumption (10–30 μL of solvent for each extraction) [75]. 
In terms of applications of greener techniques in the determination of quinolones in meat samples,  
Moema et al. applied DLLME, for determination of flouroquinolones in biological matrices (chicken 
liver) [42].  Wang et al. recently published work on the determination of four flouroquinolones in meat 
also by DLLME [82].  Thus far HF-SLM in quinolones has been applied in surface water [79], 
wastewaters [83] and biological matrices such as urine only [7].  Dispersive Liquid –Liquid 
Microextraction (DLLME) is one of the “greener” sample preparation techniques which were also 
developed to overcome the limitations of liquid phase extraction and clean-up posed by the traditional 
methods.  It is a ternary solvent, miniaturized liquid-liquid extraction method which uses microliter 
volumes of extraction solvent based on the equilibrium distribution process of the target analytes 
between sample solution and extraction solvent [84].  DLLME is similar to HF-SLM in that they 
provide high enrichment, use less solvent and are not time consuming.  On the other hand, DLLME is 
advantageous over HF-SLM due to its high efficiency in terms of sensitivity and recovery [85].  The 
main challenges that both methods presents, is extraction of analytes from biological samples which 
needs to be extracted first from the solid matrix into an aqueous phase prior to DLLME or HF-SLM 
procedure, as compared to water samples where the anaytes are in aqueous phase.   
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2.7 Analysis of quinolones 
It is very important nowadays to use sensitive and fast methods which can perform multiple-residue 
screening for determination of veterinary drugs.  For quinolones, various methods using liquid 
chromatography with UV or fluorescence detection have been developed for applications in various 
matrices and species such as bovine, porcine, poultry, fish, feed and wastewater effluents [52, 53, 86, 
87].  High performance liquid chromatography (HPLC) coupled with diode array detection (DAD) was 
also used for analysis of quinolones extracted from water by supported liquid membrane single hollow 
fibers [79].  DADs identify substances according to their retention time and their quantification is based 
on peak intensity and peak area [88, 89].  This detector is limited since it is not able to   differentiate 
between compounds which are structurally similar (i.e isomers), or those that elute at the same time 
especially during simultaneous multiple-residue analysis making it difficult to accurately identify and 
quantitate compounds.  HPLC techniques are also limited in terms of sensitivity and sample 
throughput.  
 
To improve on sensitivity and specificity, mass spectrometry (MS) became more preferred.  The 
principle of this technique is based on separation of ions in vacuum based on their mass-to-charge 
(m/z) ratios and measures the intensity of each ion.  It is a highly sensitive detector which provides 
qualitative and quantitative information concerning molecular weights and structure of compounds.   
When coupled to the LC system, parameters such as resolution in separation and quantitative 
capabilities are improved [88].   
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Liquid chromatography tandem mass spectrometers (LC-MS) utilizing to electrospray ionisation are 
increasingly being used and have become the preferred system for separating and identification of 
complex mixtures.  This kind of system is built in such a way that it can perform two or more mass 
spectrometry experiments, termed MSn which refers to its ability to perform multiple ion production 
and filtering within a single instrument [90].  Their usages are mostly in the fields of pharmaceuticals, 
environment, foods, and industrial materials.  The technique combines high specificity, sensitivity and 
allows for rapid and multiple-residue determination in complex matrices, together with structural 
information.  It is also able to perform multiple reaction monitoring (MRM), which allows for 
identification and quantification of multiple analytes in a single run, without the need to resolve them.  
These can be seen from the extensive research work done on analysis of quinolones in various matrices 
using LC-ESI-MS/MS [18, 91-97].  The sensitivity obtained for eight quinolones studied in the paper 
by Lombardo-Agui et al. ranged between 8.0 x 103 to 2.5 x 104  [97], while sensitivity obtained for four 
quinolones by Martos et al. ranged between 5.4 x 103 and 2.7 x 104 [92].  The extraction efficiencies 
obtained for four quinolones extracted from beef kidney using solid phase extraction and later analysed 
with HPLC electrospray mass spectrometry ranged from 64.1 to 143.0 % [91].  In another paper in 
which a group of veterinary drugs including four quinolones were extracted using liquid liquid 
extraction and analysed by LC-MS/MS, extraction efficiencies ranged between 60 – 80 % [94] and 
67.0 – 95.8 % [96]. 
 
The 4000 Q-trap system used in this study provides high specificity, selectivity, ability to perform 
multiple reaction monitoring (MRM) with a high level of sensitivity and is able to quantify both small 
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molecules and peptides.  As the name suggests the system is equipped with a quadrupole mass analyser.  
It is connected to an LC system and utilizes electrospray ionisation.  
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CHAPTER 3:  EXPERIMENTAL 
3.1 Materials and Reagents 
 
Enrofloxacin (ENRO) (99.0%), ciprofloxacin (CIPRO) (99.5%), norfloxacin (NORFLO) (99.8%), 
sarafloxacin hydrochloride trihydate (SARA) (97.3%), enrofloxacin-d5 hydrochloride (ENRO-d5) 
(99.3%) (IS), difloxacin-d3 hydrochloride (DIFLO-d3) (99.4%) (IS), norfloxacin-d5 (NORFLO-d5) 
(99.4%) (IS), difloxacin (DIFLO) (99.4%), danofloxacin (DANO) (99.8%), formic acid, methanol 
(LC-MS Chromasolv), phosphoric acid (85%), hydrochloric acid (37 %) were all from Fluka 
(Steinheim, Germany).  Nalidixic acid (NALI) (≥98%), acetone (LC-MS Chromasolv), triethylamine, 
sodium dihydrogen phosphate (NaH2PO4) and acetonitrile (LC-MS Chromasolv) were from Sigma-
Aldrich (Steinheim, Germany).  Sepra C18–E 50 µm, 65 Å bulk packing sorbent was from 
Phenomenex (Torrance, CA, USA).  The membrane filters, 0.45 μm Polyvinylidene Fluoride (PVDF) 
were from Acrodisc® Syringe Filters (Pall Corporation, New York, USA). 
 
Water was purified using a Waters Milli-Q purification system (Millipore, Billerica, MA, USA) at a 
resistivity of 18.2 MΩ cm-1.  The hollow-fibers made of Accurel®PP fiber, diameter of 600 μm were 
a gift from Professor Jan Ake Johnson, of the Chemistry Department, Lund University, Sweden.  
Nitrogen gas (N2) of 99.9 % purity
 used for drying samples was supplied by Air Liquide (Johannesburg, 
South Africa).   
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3.2 Instrumentation 
 
3.2.1 Mass Spectrometer  
 
 
An Applied Biosystems 4000 Qtrap mass spectrometer (Figure 3.1) was from Applied Bio systems 
/ABSciex (Pty) LTD (Darmstadt, Germany) and was used for all mass spectral measurements.  The 
mass spectrometer was equipped with a TurboV source using electrospray ionization (ESI) in positive 
ion mode.  The mass spectrometer was operated in the multiple reaction monitoring (MRM) mode to 
confirm the identity of quinolones.  This was achieved by selecting specific precursor-to-product ion 
for each quinolone and quantifying using the most abundant transition.  
  
Figure 3.1: AB Sciex 4000 Qtrap MS/MS 
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3.2.1.1 Optimization of MS/MS parameters  
 
The MS/MS parameters were generated by first infusing the standard solutions directly in the mass 
spectrometer in order to optimize the ion source parameters.  The individual analytes at concentrations 
of 10 ng µL-1  were mixed with methanol/0.1 mM ammonium formate in UHP water (50/50, v/v) using 
a 1.0 mL Hamilton syringe and pushed through a Harvard apparatus model 11 syringe pump into the 
mass spectrometer at a flow rate of 10 µL min-1  until parameters were established.  The purpose was 
to determine the precursor ions, product ions, declustering potential (DP)/cone voltage, collision 
energies (CE), cell exit potential (CXP) and dwell time.  Other parameters including ion source voltage, 
temperature (550 ̊C), ion source gas 1 (40 psi) and 2 (40 psi), curtain gas (30 psi) and entrance potential 
(10 V) were optimized on an AB Sciex API 4000 QTRAP ESI-MS/MS.   
 
3.2.2 HPLC 
 
Chromatographic analysis was carried out on an Agilent 1200 series HPLC equipped with a binary 
pump, an on-line degasser, an autosampler, automatic injector and a thermostated column 
compartment.  The system was operated with Analyst 1.5.2 software.  In preliminary studies the 
separation method was developed using a Phenomenex Luna 3μm C18 150 mm x 2.00 mm, 100 Å 
column and a gradient method consisting of mobile phase A (40 mM ammonium formate pH 2.8) and 
B (methanol + 0.1% formic acid) at a flow rate of 0.3 mL min-1, column temperature of 23 ̊C and 
injection volume of 20 μL.  Finally, LC separation of quinolones was achieved on a Phenomenex 
Kinetex 2.6 μm XB-C18, 100 mm x 4.6 mm, 100 Å column (Torrance, CA, USA) using a gradient 
elution method (Table 3.1). 
28 
 
 
Table 3.1:  Gradient profile - Mobile phase A: 0.1% formic acid in water; B: methanol; Flow rate 
400 µL min-1, injection volume 20 μL; Column temperature: 40 ̊C 
 
Step No Time (min) A (%) B (%) 
1 0.00 70 30 
2 1.00 70 30 
3 7.00 15 85 
4 9.00 15 85 
5 9.10 70 30 
6 13.10 70 30 
 
3.2.3 Other instrumentation 
 
A food chopper (Robot Coupe R201 Ultra E, France) was used for homogenising samples and an 
analytical balance from Radwag AS 220/C/2 (Poland) was used for weighing standards.  A technical 
balance from Adam PGW (Danbury, USA) was used for weighing samples, SPE bulk sorbent and 
NaH2PO4.  A centrifuge, Heraus Biofuge Primo R (Thermo Electron Corporation, Germany) capable 
of 4000 rpm and adjustable temperature between 4 - 10 °C was used for separation of the liquid from 
the solid particles.   The pH of samples and NaH2PO4 were adjusted using a Seven multi pH meter 
(Mettler Toledo, Switzerland).  The pH meter was first verified using the pH 4.0, 7.0 and 10.0 buffers.  
Verification passed when the obtained slope was 95%.  Evaporation of samples was done using a 
sample concentrator (Turbo-vapLV, Caliper Life Sciences, Charlotte, USA), and samples were mixed 
using a vortex mixer (Multireax, Heidolph Instruments, Germany) and Biomega magnetic hotplate 
stirrer (Edison NJ, USA) for stirring samples. 
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3.3 Analytical procedures 
 
3.3.1 Preparation of stock standard solutions  
 
Stock standard solutions, at a concentration of 1 mg mL-1 were prepared by accurately weighing an 
amount corresponding to 10 mg after correcting for purity, water of hydration and salts added to 
standards for each standard material (CIPRO, SARA, DANO, NORFLO, NALI) and NORFLO-d5 
(IS) (0.5 mg mL-1) into a weighing boat, dissolving and making up to 10 mL with acetonitrile/0.1% 
formic acid in water (50:50, v/v).  The same amounts of ENRO, DIFLO, DIFLO-d3 (IS) and ENRO-
d5 (IS) were dissolved and made up to volume with methanol/0.1% formic acid in water (50:50, v/v).  
The standards were stored at -20 °C until the time of analysis.   
 
3.3.2 Preparation of spiking solution and internal standards mixtures 
 
A spiking solution mixture containing all the seven analytes was prepared in a 100 mL volumetric 
flask by pipetting different volumes of the individual stock standard solution basing on the MRLs or 
action levels of each analyte, to prepare the desired concentration.  A separate mixture of internal 
standards was also prepared in a 100 mL volumetric flask.  Both solutions were prepared in methanol 
and stored at -20 ̊C.  The concentrations of the spiking solution and internal standards mixtures are as 
tabulated in Table 3.2. 
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Table 3.2: Concentrations of the spiking solution and internal standards mixtures 
Analyte 
(MRL/ 
Action level) 
Concentration of 
stock solution  
(µg mL-1) 
Aliquot from 
stock solution 
(µL) 
Final volume 
(mL) 
Final 
concentration of 
analyte (µg mL-1) 
Cipro (100) 1000 100 100 1 
Enro (100) 1000 100 100 1 
Dano (200) 1000 200 100 2 
Diflo (400) 1000 400 100 4 
Norflo (50) 1000 50 100 0.5 
Nalidixic (25) 1000 25 100 0.25 
Sara (100) 1000 100 100 1 
Enrofloxacin - d5 (IS) 1000 500 100 5 
Difloxacin – d3 (IS) 1000 500 100 5 
Norfloxacin – d5 (IS) 1000 500 100 5 
  
 
3.3.3 Preparation of 0.1 % phosphoric acid 
 
Six hundred (600) µL of phosphoric acid (85 %) was pipetted into a 500 mL volumetric flask 
containing half- filled deionised water, and made to the mark with deionised water.  This reagent was 
mixed with acetonitrile and used for extraction of the kidney samples prior to hollow-fiber procedure. 
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3.3.4 Preparation of 0.1 % formic acid 
 
Five hundred (500) µL of concentrated formic acid was pipetted into a 500 mL volumetric flask 
containing deionised water or acetonitrile.  When mixed with acetonitrile, this reagent was used 
during preparation of stock standard solutions, and when in aqueous solution it was used as a mobile 
phase.   
 
3.3.5 Preparation of sodium dihydrogen phosphate buffer (20 mM) (NaH2PO4) 
 
 
The reagent was prepared by weighing 1.2 g of sodium dihydrogen phosphate in a beaker then 
dissolving with deionised water.  The solution is then transferred quantitatively into a 500 mL 
volumetric flask and filled to the mark with deionised water.  The pH was checked and adjusted to 7.0 
with sodium hydroxide solution 
 
3.3.6 Sampling and sample preparation 
 
The bovine kidney samples were sampled from Botswana National abattoirs based on Council 
Directive 96/23/EC [12] or superseding legislation.  The directive describes that samples shall be 
properly sampled, handled properly which involves packaging and transportation in appropriate 
conditions and processed which involves proper storage conditions and sample preparation procedures 
leading to having a high chance of detecting the substance in the sample.  Sample handling procedures 
that will prevent the possibility of accidental contamination or loss of analytes are supposed to be 
created and implemented [12].  The samples were stored at -20 °C until analysis.  Blank samples were 
obtained by first screening collected bovine kidney samples using LC-ESI+MS/MS to ensure that they 
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were free of the analytes of interest.  About 10 g of various kidney samples were homogenized using 
a mini food chopper and stored at -20 °C prior to extraction.  Two grams ± 0.02 g of blank tissue 
samples were weighed into 50 mL polypropylene centrifuge tubes.  These samples were used for the 
matrix-matched calibration curve and some for the recovery studies.  For recovery studies, samples 
were spiked at ½, 1 and 1.5 MRL corresponding to 100 µL, 200 µL and 300 µL of the spiking solution 
prepared in 3.3.2, while the matrix-matched calibration samples for the calibration curve were spiked 
with 0, 100, 200, 300, 400 and 500 µL of the spiking solution.  The internal standard mixture (200 µL) 
also prepared in 3.3.2; was added to all samples including calibration standards.  Samples were vortex 
mixed to enhance interaction of analytes with the matrix. 
 
3.3.7 Developing a hollow-fiber-supported liquid membrane (HF-SLM) method 
 
Five milliliters of a mixture of 0.1% phosphoric acid: acetonitrile (30:70 v/v) followed by 10 mL of 
NaH2PO4 (pH 7) were added to the weighed and fortified 2 g kidney samples.  The samples were 
mechanically shaken with a multi reaction mixer for 10 minutes then centrifuged at 4000 rpm for 10 
minutes.  The extracted supernatants were transferred into clean tubes and their pH checked to ensure 
that they were neutral.  Hollow fibers were prepared by cutting about 4 cm length strips of the hollow 
fibers (HF), washing with acetone, drying and sealing one end using a heated spatula.  The HFs were 
impregnated with the membrane by dipping in a liquid membrane (triethylamine) for a few seconds 
then filled with ~ 20 µL of the acceptor solution (0.1 % formic acid) using a syringe.  Excess of the 
liquid membrane was then washed off with water.  The HF, supported by a needle, was immersed in 
the bottle containing the sample solution (donor phase).  The samples were stirred using a magnetic 
stirrer at 200 rpm for 1 hour.  Using a syringe, the samples (10 µL) were pushed through the HF into 
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a glass insert and analysed.  In order to obtain good results in HF-SLM, key parameters have to be 
optimised as described in the next section. 
 
3.3.8 Optimisation of hollow-fiber supported liquid membrane 
 
It is important to optimize parameters that affect quality of results of HF-SLM.  The optimized 
parameters are as described below. 
 
3.3.8.1 Selection of liquid membrane  
 
 
Triethylamine (TEA) and diethyl ether (DEE) were investigated as possible liquid membranes.  The 
experiments were performed in such a way that some parameters were held constant while varying the 
liquid membranes.  Formic acid (0.1%) was used as the acceptor phase, while NaH2PO4 was used as a 
donor phase.  Extraction or stirring was done for 1 hour.  Six bovine kidney samples (2 g) were 
weighed, fortified with spiking solution containing seven analytes as well as internal standards mixture 
and subjected to the HF-SLM procedure as described in 3.3.7 above.  Half of the samples were 
subjected to triethylamine as a liquid membrane while the other half was used with diethyl ether. 
 
3.3.8.2 Optimisation of pH of donor phase 
 
 
It is very necessary to adjust pH of the sample in LPME in so as to increase the diffusion rate of 
analytes passing through the liquid membrane into the acceptor phase [77].  To select an optimum pH 
at which all compounds will be extracted efficiently, the pH of the aqueous buffer (NaH2PO4) (donor 
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phase) was optimized between pH 2 and 10 using 3 samples per pH, a total of twenty seven (2 g) 
bovine kidney samples.  The samples were fortified with spiking solution containing seven analytes as 
well as internal standards mixture and subjected to the HF-SLM procedure as described in 3.3.7 above.  
The pH of NaH2PO4 was adjusted with acetic acid to lower the pH and increased with sodium 
hydroxide solution. Other parameters; liquid membrane (triethylamine), extraction time (1 hour) and 
acceptor phase (0.1% formic acid) were held constant. 
 
3.3.8.3 Optimization of pH of selected acceptor 
 
 
The performance of 0.1% formic acid (pH 3.0), 0.1% acetic acid (pH 3.0) and 0.1 M hydrochloric acid 
(pH 3.0) as the acceptor phase was investigated.  Nine 2 g bovine kidney samples were weighed, 
fortified with spiking solution containing seven analytes as well as internal standards mixture and 
subjected to the HF-SLM procedure as described in 3.3.7 above.  Three samples were used with each 
acceptor phase.  The liquid membrane (triethylamine), donor phase (NaH2PO4) and stirring time of 1 
hour were kept constant during this experiment.  The pH of the acid which gave good extraction 
efficiencies was further optimized between pH 2 and 6 by using 15 extracted samples and subjecting 
them to the hollow fiber supported liquid membrane procedure again as described in 3.3.7 above. 
  
3.3.8.4 Effect of extraction (stirring time)  
 
 
To determine extraction time of analytes, time was varied between 30 and 120 minutes to achieve an 
optimum extraction time.  Optimization of extraction time was done using TEA as the liquid 
membrane, NaH2PO4 (pH 7) as the donor phase and 0.1 % formic acid (pH 3) as the acceptor phase.  
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Nine 2 g bovine kidney samples were weighed, fortified with spiking solution containing seven 
analytes as well as internal standards mixture and subjected to the HF-SLM procedure as described in 
3.3.7 above.  The samples were equally divided among the three extraction times.  
 
3.3.9 Developing a dispersive solid phase extraction (dSPE) method  
 
Another sample extraction/ clean-up method; dispersive solid phase extraction (dSPE) was developed 
as described below and later the performance merits of the two methods were evaluated.  Ten 
millimeters of a mixture of water/acetonitrile (2:8 (v/v)) were added to the weighed 2 g tissue samples 
fortified with a spiking solution containing seven analytes as well as internal standards mixture.  
Samples were mechanically shaken with a multi reax mixer for 10 minutes followed by centrifugation 
at 5 °C, 4000 rpm, for 10 minutes.  The supernatants were transferred into labeled 15 mL polypropylene 
centrifuge tubes containing 500 mg Sepra C18 SPE sorbent (BondElut) and vortexed for 5 minutes.  
The mixture was centrifuged again at 5 °C, 4000 rpm, for 5 minutes and 5 mL aliquot of the resulting 
supernatant was transferred into a test tube.  The contents were evaporated down to 1 mL under a 
stream of N2 using Turbo-vap LV with a water bath set at 40°C.  The samples were then filtered through 
0.45 μm PVDF membrane filters prior to injecting 20 µL into LC-MS/MS for analysis.  The described 
procedure was adopted from Zhou et.al, Phenomenex applications note [98].  Figure 3.2 below shows 
a flow diagram for a typical dSPE method. 
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Figure 3.2:  Flow diagram of dispersive solid phase extraction (dSPE) [99] 
 
3.4 Method validation for HF-SLM and dSPE 
 
Council directive 2002/657/EC guidelines describes parameters which were subjected to the HF-SLM 
and dSPE methods to validate their performance [13].  These parameters include; calibration function, 
identification, specificity, linearity, precision, accuracy and analytical limits.  The precision of the 
method was evaluated in terms of repeatability (single day or intraday precision) and within-laboratory 
reproducibility (different days - interday precision). Analytical limits studied covered limit of detection 
(LOD), limit of quantification (LOQ), decision limit (CCα) and detection capability (CCβ).  Validation 
was done for both HF-SLM and dSPE methods. 
Homogenize sample 
Transfer sample to 50 mL tube 
Centrifuge and transfer supernatant 
to d-SPE clean-up tube 
Spike samples and add extraction 
solvent, and shake 
Shake and centrifuge 
LC-MS/MS analysis 
Dilute extract with mobile phase 
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CHAPTER 4: RESULTS AND DISCUSSION 
 
4.1 Mass spectral analysis 
 
The optimized parameters of the seven quinolone compounds studied are as shown in Table 4.1 while 
Table 4.2 shows retention times and MRM transitions obtained for each analyte.  Two MRM transitions 
were selected for each analyte.  The most intense transition was used for quantification while the minor 
for confirmation (identification) of the analytes. 
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Table 4.1:  Optimized MS parameters of each analyte 
 
Analyte & 
Molecular 
weight (g mol-1) 
MS Parameters 
Q1 Mass 
(m/z) 
Q3 Mass 
(m/z) 
Dwell time 
(msec) 
DP (V) CE (V) CXP (V) 
Enrofloxacin 
359.4 
360 342 50 81 27 8 
360 316 50 81 37 20 
360 245 50 81 31 8 
Ciprofloxacin  
331.34 
332 314 50 81 29 8 
332 288 50 81 27 8 
332 231 50 81 53 20 
Difloxacin 
399 
400 356 50 101 29 14 
400 382 50 101 31 16 
400 299 50 101 37 8 
Danofloxacin 
357 
358 340 50 86 31 20 
358 82 50 86 71 14 
358 314 50 86 27 8 
Norfloxacin 
319 
320 302 50 66 29 18 
320 276 50 66 25 24 
320 233 50 66 35 18 
Sarafloxacin 
385.36 
386 368 50 81 27 10 
386 342 50 81 33 10 
386 298 50 81 39 8 
Nalidixic acid 
232.24 
233 215 50 46 21 18 
233 187 50 46 37 14 
233 104 50 46 59 8 
Enrofloxacin-d5   
359 
365 347 50 61 29 30 
365 321 50 61 29 26 
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Analyte & 
Molecular 
weight (g mol-1) 
MS Parameters 
Q1 Mass 
(m/z) 
Q3 Mass 
(m/z) 
Dwell time 
(msec) 
DP (V) CE (V) CXP (V) 
Norfloxacin-d5 
323 
325 307 50 51 31 18 
325 231 50 51 55 12 
Difloxacin-d3 
399 
403 385 50 61 33 22 
403 359 50 61 29 18 
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Table 4.2: MRM transitions, collision energies and retention times of each analyte 
 
Key:  ENR-d5   Enrofloxacin-d5;  DIF-d3     Difloxacin-d3;  NOR-d5    Norfloxacin-d5    
  
Analyte and  
Molecular 
Weight  
(g mol-1) 
Retention 
time 
(tR, min) 
Internal  
Standard 
used 
 
Quantification 
ion (Q1)(m/z) 
 
Collision 
Energy 
(CE) (V) 
Identifying 
Ion 
(Q3)(m/z) 
 
Collision 
Energy  
(CE) (V) 
Enrofloxacin 
359.4 
4.40 ENR-d5 360        342 27 360          316 37 
Ciprofloxacin  
331.34 
4.28 ENR-d5 332        314 29 332          288 27 
Difloxacin 
399 
5.31 DIF-d3 400        356 29 400         382 31 
Danofloxacin 
357 
4.54 DIF-d3 358       340 31 358         82 71 
Norfloxacin 
319 
3.91 NOR-d5 320       302 29 320         276 25 
Sarafloxacin 
385.36 
5.75 DIF-d3 386        368 27 386        342 33 
Nalidixic acid 
232.24 
8.97 NOR-d5 233        215 21 233         187 37 
Enrofloxacin-d5   
359 
4.34  365        347 29 365         321 29 
Norfloxacin-d5 
323 
3.78  325         307 31 325        231 55 
Difloxacin-d3 
399 
5.25  403         385 33 403         359 29 
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4.2 Chromatographic separation 
 
Despite testing several gradient elution programs and varying the pH of mobile phase using the 
Phenomenex Luna 3 μm C18, 150 mm x 2.0 mm, 100 Å column, the quinolones under study could not 
be resolved.  Changing the stationary phase to an Agilent Zorbax Eclipse 1.8µm XDB-C18 50 mm x 
4.6 mm   column did not improve the separation.  The separation greatly improved when the column 
was changed to Phenomenex Kinetex 2.6 μm XB-C18, 100 mm x 4.6 mm, 100 Å. 
 
Under these conditions seven quinolones; (enrofloxacin, ciprofloxacin, danofloxacin, difloxacin, 
norfloxacin, nalidixic acid and sarafloxacin) and three internal standards (difloxacin-d3, norfloxacin-
d5 and enrofloxacin-d5) were separated (Figure 4.1).  Separation of the ten analytes was finally 
achieved using a modified method from Phenomenex applications note [100].  A gradient method was 
developed using a Phenomenex Kinetex 2.6 μm XB-C18,100 mm x 4.6 mm, 100 Å column consisting 
of mobile phase A (0.1% formic acid in water) and B (methanol), at a flow rate of 0.4 mL min-1, 
injection volume of 20 µL.  Column temperature was optimized at 40 ̊C.  The developed separation 
method and the optimized LC-MS/MS conditions were used in the present study.  Co-elution was still 
observed with some compounds such as enrofloxacin and ciprofloxacin due to the structural similarity 
of the two analytes.  Good intensities for all analytes ranging from 1.0 x 105 for norfloxacin as the 
lowest to 9.3 x 105 for nalidixic acid as the highest, as well as good peak shapes were obtained.  Internal 
standards were used in this study because they are useful in mass spectrometry during quantification.  
They are used to account for various method variables such as variability in extraction efficiency, 
matrix suppression, variability in injection volume, recovery during transfer of samples from one tube 
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to another as well as pipetting and clean-up stages [101].  It is normally added at the beginning of 
sample preparation before extraction to all samples, blanks and calibration standards at the same 
concentration level.  During data analysis, peak ratios (i. e analyte concentration against internal 
standard concentration) are used in order to account for any loss of analytes that may have occurred at 
any stage during analysis because the same fraction of each is believed to be lost in any operation 
[102].   
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Figure 4.1  Chromatogram showing separation of 10 compounds (7 quinolones plus 3 internal 
standards) using Phenomenex Kinetex 2.6 μm XB-C18, 100 mm x 4.6 mm, 100Å.  Mobile phase: A 
(0.1% formic acid in water) and B (methanol), at a flow rate of 0.4 mL min-1, injection volume of 20 
µL and column temperature was optimized at 40 C̊. 
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4.3 Optimization of hollow fiber- supported liquid membrane (HF-SLM) 
 
A hollow fiber-supported liquid membrane method was developed and optimised for the extraction of 
quinolones from bovine kidney.  The results are discussed in the next section below.  
   
4.3.1 Selection of liquid membrane  
 
In this study, a three-phase HF-SLM extraction system was used [66].  Selection of a liquid membrane 
is based on the following characteristics; (a) it should be immiscible with water and of low polarity to 
ensure that it remains within the pores of the fiber during extraction with no leakage to the aqueous 
sample, (b) less volatile to prevent evaporation and (c) low viscosity to ensure high and fast flow of 
analytes in one direction termed “rapid mass transfer” [15, 77].  Two solvents were investigated as 
possible liquid membrane; triethylamine (TEA) and diethyl ether (DEE).  0.1 % formic acid (pH 3.0) 
was used as an acceptor phase and NaH2PO4, as the donor phase at pH 7.0.  Samples were stirred for 1 
hour.  Figure 4.2 compares the extraction efficiencies of seven quinolones when using triethylamine 
and diethyl ether as the liquid membranes.  It is evident that five of the compounds, viz ciprofloxacin, 
danofloxacin, difloxacin, enrofloxacin and sarafloxacin were extracted better with triethylamine (% 
EF ranging from 88 – 118 %.) compared to diethyl ether which gave EFs of 37 to 109 %.  The observed 
extraction efficiencies can be explained by the solubilities and hydrophobicities of the analytes.  The 
solubility of sarafloxacin, difloxacin, nalidixic acid, enrofloxacin and norfloxacin in water at 25 °C are 
very low (i.e. 1, 5, 0.1, 0.15 and 0.28 [103, 104] mg mL-1 respectively, and therefore would be expected 
to be partitioned more into the organic phase.  According to Sarafraz-Yazdi and Amiri, hydrophobic 
analytes are easily extracted into organic solvents from aqueous solutions [15], as observed with high 
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extraction efficiencies of sarafloxacin (110 %), difloxacin (118 %) and enrofloxacin (118 %) which 
are more hydrophobic.  The opposite was observed for ciprofloxacin and danofloxacin which have 
high solubilities in water but did not extract well in diethyl ether.  Both analytes extracted well in 
triethylamine with extraction efficiencies of 88 and 101 % respectively.  The solubility for 
ciprofloxacin in water is 30 mg mL-1 at 20 °C while that of danofloxacin is 156.0 mg mL-1 at pH 5.  
Their good extraction efficiencies could have been enhanced by diffusion through a membrane solvent 
(triethylamine) which is less soluble in water (more hydrophobic) in comparison to diethyl ether 
(solubilities: 5.5 g 100 g-1 (25 ̊C) for triethylamine [105] and 6.05 g 100 mL-1 (25 ̊C) for diethyl ether).  
Nalidixic acid and norfloxacin were extracted more favorably in diethyl ether with extraction 
efficiencies of 98 and 97 % respectively as compared to 57 and 56 % respectively in triethylamine.  
These can be explained by that though both nalidixic acid and norfloxacin have low solubility in both 
water and ethers (0.1 and 0.01mg mL-1 [104] respectively), that is more hydrophobic, back extraction 
or diffusion seemed to be less in diethyl ether than in triethylamine leading to them being extracted 
more in diethyl ether.  Overall triethylamine was selected as the liquid membrane for all the work as it 
gave better results for most analytes than diethyl ether and also because it is more hydrophobic 
compared to diethyl ether. 
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Figure 4.2: Selection of liquid membrane; TEA (triethylamine); DEE (Diethyl ether); NaH2PO4 
pH 7 (donor phase), 0.1 % formic acid (acceptor phase), 60 minutes stirring time. 
 
4.3.2 Effect of pH of donor phase 
 
 
To select an optimum pH at which all compounds will be extracted efficiently, the pH of donor phase 
has to be optimised such that pH > pKa + 3.3 [106].  The principle of HF-SLM requires that analytes 
in the donor phase be in a neutral state (around pKa values) for them to diffuse through the supported 
liquid membrane into the acceptor phase [106, 107].  The pKa values of quinolones ranges from 6 to 
9 (Table 2.1) making them neutral between pH 7 to 8.  The pH of NaH2PO4 (donor phase) was therefore 
varied between 2 and 10.  Triethylamine was used as a liquid membrane, 0.1 % formic acid (pH 3.0) 
as an acceptor phase and stirring time of 1 hour.  Figure 4.3 shows the extraction efficiencies obtained 
with variation of pH of the donor phase.  The extraction efficiencies increased from pH 2 up to pH 7 
and then decreased under alkaline conditions.  The obtained extraction efficiencies for all compounds 
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at pH 7 ranged between 89 - 116 %.  Ciprofloxacin was not extracted at all at pH 3.  According to 
literature, it has been found that most quinolones have four ionisable functional groups, one carboxylic 
group and three basic nitrogen sites (Table 2.1) leading to four pKa values.  Ciprofloxacin has four pKa 
values (3.01, 6.14, 8.7 and 10.58) [40].   Thus at pH 3 of the donor phase (which was equal to that of 
the acceptor phase) ciprofloxacin could not be extracted at all, because there was no driving force by 
the proton gradient which is required to transport analytes in one direction (from the donor to acceptor 
phase) since the pHs were equal.  The pKa of other analytes are greater than 3, therefore at pH 3, they 
were able to be extracted into the acceptor phase.  For analytes to be extracted the pH of the sample 
must be adjusted to a value sufficiently high such that the analytes are uncharged, and can be extracted 
into the liquid membrane [108].  A similar trend was observed and reported by Poliwoda et. al when 
they studied the influence of donor phase pH on four flouroquinolones using HF-SLM.  The 
enrichment factors were observed to increase from pH 2 until they reached a maximum at pH 6 then 
decreased [79] similar to what was observed in this study.  It has been observed in literature that higher 
pH values (i.e. pH 10) resulted in membrane destabilization [79] which has been observed with 
norfloxacin and sarafloxacin under this pH since they were not extracted at all.  For the rest of the 
study pH 7 was chosen as the optimum for the donor phase since it gave superior extraction efficiencies 
for all the analytes. 
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Figure 4.3:  Optimization of pH of NaH2PO4 (donor phase) from pH 2 to 10; triethylamine (liquid 
membrane); 0.1 % formic acid (acceptor phase); 60 minutes stirring time 
 
4.3.3 Effect of pH of selected acceptor phase 
 
 
Three acids were investigated as possible acceptor solutions.  Acids were used in this case so as to 
enhance extraction of basic analytes from the organic (liquid membrane) phase into the acceptor 
solution.  Figure 4.4a shows the results from all three acids which gave reasonably good extraction 
efficiencies (76 -113 %) for all analytes except nalidixic acid which was less extracted in acetic and 
hydrochloric acids with extraction efficiencies of 10 and 38 % respectively.  Nalidixic acid is 
structurally different from other quinolone antibiotics, it is also more acidic with a pKa of 5.95 [43].  
In HF-SLM, nalidixic acid will extract well with a basic acceptor phase of a higher pH (i.e pH >10) 
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than a lower pH.  Formic acid (0.1 %) was then chosen as the optimum acceptor phase and also for its 
compatibility with LC-MS/MS.  Formic acid was further investigated by varying the pH in the range 
of 2 to 6 to obtain the optimum condition.  The extraction efficiencies obtained are shown in Figure 
4.4b.  It can be observed that at pH 3 extraction efficiencies ranging from 85 – 112 % were obtained 
for all analytes.  This can be explained by the concept of mass transfer (net diffusion across the 
membrane or phase), whereby in order to obtain a high mass transfer the presence of proton gradient 
between the acceptor and donor phase is essential to ensure that transport of analytes goes only in one 
direction.  The proton or concentration gradient is responsible for the driving force of the process [79, 
107, 109].  Thus the pH of the acceptor phase (i.e. 0.1 % formic acid, pH 3) should be lower than that 
of the donor phase (i.e. NaH2PO4, pH 7), to enhance extraction of analytes in one direction; since a 
higher pH in the donor phase suppresses solubility of the analytes whereas a lower pH in the acceptor 
phase promotes solubility and this enhances extraction of basic compounds into the membrane solvent 
and further into the acceptor phase without back-extraction to the membrane solvent [15].   
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Figure 4.4a:  Selection of acceptor phase (i) 0.1 M HCl  (ii) 0.1% acetic acid  (iii) 0.1% formic 
acid; triethylamine (liquid membrane), NaH2PO4 pH 7 (donor phase), 60 minutes 
stirring time 
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Figure 4.4b:  Optimization of pH of selected acceptor phase (0.1% formic acid) between pH 2 to 
6; triethylamine (liquid membrane), NaH2PO4 pH 7 (donor phase), 60 minutes 
stirring time. 
 
4.3.4 Evaluation of extraction time 
  
 
To determine the total extraction time of analytes, a principle of “equilibrium extraction through 
membrane” [66] led to varying the extraction time from 30 to 120 minutes to achieve an optimum 
extraction time since extraction of analytes through the membrane is time dependent.  Optimization of 
extraction time was carried out using TEA as the liquid membrane, 0.1% formic acid as the acceptor 
phase at pH 3.0 and NaH2PO4 pH 7 as the donor phase.  From the results in Figure 4.5, it can be 
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observed that extraction efficiencies increased with time from 30 to 60 minutes, then decreased 
between 60 and 120 minutes.  The observed trend can be perfectly backed up by the statement by Ho 
et.al which states that “LPME is an equilibrium extraction technique, and the recovery increases 
rapidly with increasing extraction time up to a certain level where the recovery versus time gradually 
decreases and the extraction system enters an equilibrium state” [77].  Another concept from Jönsson 
.et. al. also explains the trend observed in terms of concentration profile in the donor channel being 
constant with time also leading to constant extraction efficiency and a linear increase of the 
concentration in the acceptor channel with time [107] which both shows complete trapping of analytes 
in the acceptor channel.  These conditions are obviously desirable in practical application of the 
technique.  With incomplete trapping, the extraction efficiency will decrease with time until a sufficient 
concentration in the acceptor channel is reached, representing equilibrium concentrations of the analyte 
in all three phases and, consequently, zero flux [107].  Most analytes were well extracted within 60 
minutes with extraction efficiencies ranging from 55 -118 %.  This time (i.e. 60 minutes) was therefore 
selected as the optimum and used for the rest of the investigations in this work.  The HF-SLM optimum 
conditions were therefore; NaH2PO4 at pH 7 as the donor phase, triethylamine as the liquid membrane, 
0.1 % formic acid at pH 3 as the acceptor phase, and extraction time of 60 minutes.  These optimum 
conditions were used for validation and applicability of the method to real samples. 
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Figure 4.5:  Effect of extraction time (i) 30 minutes (ii) 60 minutes (iii) 120 minutes; 
triethylamine (liquid membrane), NaH2PO4 pH 7 (donor phase), 0.1 % formic acid 
pH 3 (acceptor phase). 
 
4.4 Method validation for HF-SLM 
 
4.4.1 Linearity 
 
 
The linearity of the method was evaluated using a nine point matrix-matched calibration curve constructed 
by spiking a blank kidney sample with quinolones standard solution at 0, ¼, ½, ¾, 1, 1.5, 1.75, 2.0 and 
2.5 MRL or action level (i.e. covering a concentration range of 12.5 - 1000 µg kg-1 for all analytes).  Each 
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concentration level had nine replicates.  Coefficients of determination (r2) for all curves were greater than 
0.97 (Table 4.3).  This demonstrates linearity of the detector response over the concentration range 
analysed and gives confidence in the ability of the method to quantitate.  
 
4.4.2 Limit of detection (LOD) and limit of quantification (LOQ) 
 
 
The HF-SLM was validated for the limit of detection (LOD) and the limit of quantification (LOQ).  
The LOD is the lowest quantity of a substance that can be distinguished from the sample in the absence 
of that substance (a blank value) within a stated confidence limit (generally 1%) while limit of 
quantification (LOQ) is the limit at which we can reasonably tell the difference between two different 
values [13] or the smallest analyte concentration that can be quantified with a given confidence level.  
Both limits can be determined by the standard error approach using the calibration curve [110].  
According to this approach the limit of detection is defined by;  
 
LOD = 3.3*(Sy/m)      (1) 
 
 and the limit of quantification is defined by  
LOQ = 10*(Sy/m)       (2) 
 
Where m is the slope of the calibration curve and Sy is the standard error of the calibration curve 
given by the equation below; 
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                (Yi - mxi - b)2 
            Sy =    ∑                                                                                                          (3) 
      √               n - 2 
 
                   
Where: Yi is the y value, Xi is the x value, b is the y intercept, m is the slope and n is number of the 
degrees of freedom [13]. 
 
Alternatively, LOD and LOQ can be calculated using the standard deviation of concentration of seven 
blank samples at the lowest calibration level using the formulas below: 
 
LOD = Concblank + 3 (SD blank/lowest standard).                                  (4) 
 
LOQ = Concblank + 10 (SD blank/lowest standard).                                (5) 
 
Where; Concblank is the concentration of the blank sample, SDblank is the standard deviation of the 
blank, 3 is the signal-to-noise ratio for limit of detection, and 10 is the signal-to-noise ratio for limit of 
quantification.   
 
Equations (1), (2) and (3) were used to calculate LOD and LOQ.  Table 4.4 shows LOD and LOQ 
values obtained in this work which ranged from 3 to 39 µg kg-1 and 11 to 130 µg kg-1 respectively.  
These values are much higher for some analytes in comparison to data reported by other authors.  
Examples in literature where similar analytes have been determined in distilled water, surface water, 
wastewater and bovine urine using HF-SLM with HPLC obtained the following LODs; ciprofloxacin 
3 ng L-1 (LOD in distilled water) and 10 ng L-1 (LOD in surface water and urine samples); danofloxacin 
5 ng L-1 (LOD in distilled water) ,7 ng L-1 (LOD in urine samples) and 13 ng L-1 (LOD in surface 
water); enrofloxacin 7 ng L-1 (LOD in urine samples,13 ng L-1 (LOD in distilled water) and 25 ng L-1 
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(LOD in surface water) [7, 79].  This trend is expected since water matrices are less complex compared 
to biological matrix such as bovine kidney leading to higher detection and quantification limits.  Some 
researchers employed solid phase extraction in swine kidney followed by LC-MS/MS.  The LODs 
reported were not significantly different for the same analytes studied (i.e. ciprofloxacin <15 µg kg-1; 
enrofloxacin <10 µg kg-1; nalidixic acid <10 µg kg-1; norfloxacin <10 µg kg-1 [50]) while for 
danofloxacin the value differed significantly (i.e. danofloxacin <10 µg kg-1 [50]).  The LODs and 
LOQs obtained for quinolones extracted by liquid-liquid extraction from chicken muscle and followed 
by LC-MS/MS were as low as (0.2 - 1.5) and (0.7 – 5.0) µg kg-1 respectively for ciprofloxacin, 
danofloxacin and enrofloxacin [94].  The observation made with regard to the low LOD and LOQ 
values in the paper by Chiaochan et.al [94] was that the linearity range used was lower (1 -100 µg kg-
1) compared to the linearity range used in this study which ranges from 12.5 as the lowest to 1000 µg 
kg-1 as the highest, for the various analytes as shown in Table 4.3.   Linearity range influences the 
values of LODs and LOQs in that they can be calculated based on the response obtained from the 
calibration curve to estimate the standard error, then dividing the error with the slope of the curve, 
multiplied by 3 (LOD) or 10 (LOQ) signal-to-noise ratio.  The response for a calibration curve with a 
lower linearity range will be lower, leading to low LOD and LOQ and vice versa.  These limits can 
also be estimated by analysing spiked blank sample at the lowest calibration level and determining the 
concentration of each analyte which provided signals with S/N equal to 3 and 10 respectively as was 
the case in the paper by Chiaochan et. al.  Higher linearity ranges used in this study were based on the 
MRL/action levels of the analytes as stipulated in EU directives. 
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Table 4.3: Summary of the validated parameters 
 
Compound Linear range, 
(µg kg-1) 
Regression equation R2 LOD,  
(µg kg-1) 
LOQ,  
(µg kg-1) 
CIPRO 50-250 y = 0.00184x + (-0.0115) 0.9929 17 58 
ENRO 50-250 y = 0.00346x + 0.0249 0.9781 12 41 
DANO 100-500 y = 0.00755x + (-0.0479) 0.9955 28 95 
DIFLO 200-1000 y = 0.00262x + (-0.00584) 0.9975 39 130 
NORFLO 25-125 y = 0.00212x + (-0.0162) 0.9714 4 13 
NALI 12.5-62.5 y = 0.0972x + 0.2070 0.9888 3 11 
SARA 50-250 y = 0.00368 + (-0.00506) 0.9910 18 61 
 
4.4.3 Precision study 
 
 
Precision was estimated by fortifying blank kidney samples at three different levels (0.5, 1.0 and 1.5 
times the MRL) in seven replicates at each level for three days.  Repeatability (within batch) was 
calculated as the relative standard deviation (RSD) of results obtained for each analyte at each level 
after replicates (n = 7) were analysed under the same conditions, same operator, and on the same day.  
The RSD was calculated from the mean concentration of each batch.  The RSDs obtained ranged from 
1 – 23% which fall within the recommended limits of ≤ 23% as stipulated by the European Commission 
2002/657/EC (Table 4.4).  This shows that the method has good repeatability. 
 
Two analysts were involved for within laboratory reproducibility.  Moreover, for the mobile phase and 
extraction purposes, different batches of acetonitrile and methanol were used.  Within –laboratory 
reproducibility was calculated as %RSD of analysis done at two concentration levels (0.5 MRL and 
1.0 MRL) over a period of three days.  The RSDs obtained also ranged from 2 – 15% which fall within 
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the recommended limits of ≤ 23% as stipulated by the European commission 2002/657/EC (Table 4.5) 
showing that the method is reproducible.  
 
Table 4.4: Intraday precision of HF-SLM method 
Analyte MRL/action 
level  (µg kg-1)                                                                   
Mean Ccalculated 
(n =  7)
SD %RSD 
CIPRO 100 99 11.6 11.7 
ENRO 100 96 7.44 7.75 
DANO 200 191 24.7 12.9 
DIFLO 400 412 17.5 4.25 
NALI 25 27 3.76 13.9 
NORFLO 50 53 7.61 14.4 
SARA 100 99 7.42 7.49 
     
Note: Ccalculated- calculated concentration (µg kg
-1) 
 
 
59 
 
Table 4.5: Reproducibility of HF-SLM  
_________________________________________________________________________________ 
 Mean conc. at MRL/action level (obtained in 3 days)   
Analyte Day 1 
(Batch) 
Day 2 
(Batch) 
Day 3 
(Batch) 
Mean Conc 
(n = 3) 
SD % RSD 
 (n = 7 for each day)    
CIPRO 99 101 102 101 1.53 1.51 
ENRO 96 112 102 103 8.08 7.8 
DANO 191 184 204 193 10.1 5.23 
DIFLO 412 388 371 390 20.6 5.28 
NALI 27 24 27 26.0 1.73 6.65 
NORFLO 53 54 50 52.5 2.08 3.98 
SARA 99 100 101 100 1 1 
       
Note: Conc. - concentration 
_________________________________________________________________________________ 
4.4.4 Accuracy 
 
 
Accuracy is determined using a Certified Reference Material (CRM).  Unfortunately, there was no 
CRM available in this study.  To determine trueness, accuracy was evaluated by spiking samples with 
standard solutions and calculating the recoveries.  Seven replicates of bovine kidney samples were 
spiked at three levels (0.5, 1 and 1.5 MRL) (n = 21).  The recoveries were calculated from the peak 
ratios obtained from a spiked matrix-matched calibration curve.  Table 4.6 shows mean % recoveries 
for all quinolone analytes at three spiking levels (0.5, 1 and 1.5 MRL) using HF-SLM.  Recoveries for 
all the analytes at the three concentration levels were in the range of 89-107 % which fall within the 
recommended acceptable range of 80-110 % as stipulated in EU commission 2002/657/EC.   
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Table 4.6:  Recoveries (%) of extracted quinolones from bovine kidney at ½, MRL and 1.5 MRL 
spiking levels. (n = 21) 
 
Analyte HF-SLM % Mean recovery  
 ½MRL MRL 1.5MRL SD 
CIPRO 95 91 100 4.51 
ENRO 106 103 107 2.21 
DANO 98 89 101 6.51 
DIFLO 100 100 100 0 
NALI 100 104 99 2.61 
NORFLO 95 105 98 5.17 
SARA 100 100 94 2.28 
 
4.4.5 Decision limit (CCα) and Detection capability (CCβ) 
 
 
Decision limit (CCα) means the limit at and above which it can be concluded with an error probability 
of (α = 95%) that a sample is non-compliant, as defined in the European Union Commission Decision 
2002/657/EC directive [13].  CCα can be defined by the following equation; 
 
CCα = CMRL + 1.64SD (at MRL)    (6) 
 
which states that; the corresponding concentration at the permitted limit plus 1,64 times the standard 
deviation of the within-laboratory reproducibility equals the decision limit (α = 5 %) from the plotted 
curve. 
 
On the other hand, detection capability (CCβ) also as defined in the European Union Commission 
Decision 2002/657/EC directive; means the smallest content of the substance that may be detected, 
identified or quantified in a sample with an error probability of (β = 95%).  This means that the 
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detection capability is the concentration at which the method is able to detect permitted limit 
concentrations with a statistical certainty of (β = 5%) [13].  The CCβ is therefore defined by the 
equation; 
 
CCβ = CCα + 1.64SD (at CCα)      (7)  
 
The decision limits (CCα) and detection capability (CCβ) were calculated using calibration curve 
procedure according to ISO 11843 [111].  Seven replicates of a blank kidney sample were fortified 
around the MRL in equidistant steps (0.5, 1.0, and 1.5 MRL).  Samples were analysed and after 
identification calibration curves were plotted (peak ratio against concentration).  Table 4.7 shows 
values obtained for CCα ranging from 28 µg kg-1 to 422 µg kg-1 and CCβ ranging from 29 µg kg-1  to 
454 µg kg-1.  These values are useful for interpretation of results by qualifying the results as compliant 
or non-complaint.  For example, if the results for enrofloxacin (MRL – 100 µg kg-1) obtained for a 
certain sample is found to be 127 µg kg-1, the results will be interpreted as non-compliant since the 
result is above the validated CCβ (125 µg kg-1).  If the value is above CCα (114 µg kg-1) but below 
CCβ, the results are interpreted as false positive and are compliant. 
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Table 4.7: CCα and CCβ of quinolones obtained with HF-SLM method. 
 
 MRL/ action 
level (µg kg-1) 
Mean CMRL 
(µg kg-1) 
SD within –lab 
reproducibility 
CCα (µg kg-1) CCβ (µg kg-1) 
Analyte 
n=7 
CIPRO 100 101 15 126 150 
ENRO 100 103 7 114 125 
DANO 200 193 5 201 210 
DIFLO 400 391 19 422 454 
NALI 25 26 1 28 29 
NORFLO 50 52 1 54 56 
SARA 100 100 0 123 146 
Note:  CMRL – concentration at MRL level 
 
4.5 Method validation for dSPE  
 
Validation for dSPE was done following the same procedure used for validation of HF-SLM method.  
Table 4.8 shows the summary of all the validated parameters for dSPE method. 
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Table 4.8:  Summary of validated parameters for dSPE method  
Analyte 
(MRL/ 
action 
level) 
Validated parameters  
% mean 
recovery 
at MRL/ 
action 
level r2 LOD LOQ 
Reprod 
(% RSD) 
at MRL/ 
action 
level 
Repeat 
(% 
RSD) at 
MRL/ 
action 
level 
CCα  
(µg kg-1) 
 
CCβ  
(µg kg-1)  
 
Cipro 
(100) 106 0.9969 12 40 22 13 
 
127 
 
149 
Enro 
(100) 103 0.9986 
 
10 33 7 2 
 
107 
 
111 
Dano 
(200) 96 0.9963 37 74 17 6 
 
218 
 
227 
Diflo 
(400) 114 0.9735 39 130 25 21 
 
429 
 
464 
Nali  
(25) 100 0.9955 3 10 1 1 
 
27 
 
30 
Nor  
(50) 101 0.9966 3 10 5 5 
 
58 
 
66 
Sara 
(100) 110 0.9811 6 19 17 5 
 
117 
 
125 
 
 
The LOD values obtained for ciprofloxacin, enrofloxacin, nalidixic acid and norfloxacin were 
comparable to the values obtained in a study for determination of flouroquinolones in swine kidney 
using solid phase extraction analysed by LC-MS/MS [50].  The LOD for danofloxacin is not 
comparable since the values differ by a magnitude of 33.  Difloxacin and sarafloxacin were not studied 
in the same paper.    
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4.6 Comparison of HF - SLM with dSPE using student t-test  
 
From the validation data obtained for the two methods, it can be noted that both methods gave good 
recoveries ranging between 89 – 114 % for all analytes studied, though the recovery for difloxacin 
(114% when using dSPE) went beyond the acceptable limit of 80-110 % as set in the EU commission 
2002/657 EC.  The obtained LODs are comparable between the two methods for some analytes (i.e. 
ciprofloxacin, enrofloxacin, difloxacin, norfloxacin and nalidixic acid) since they differ by a difference 
ranging between 0 - 12 µg kg-1.  This close agreement in LOD values was also observed in a paper by 
van Vyncht on analysis of fluoroquinolones in swine kidney using Solid Phase Extraction analysed by 
LC-MS/MS [50].  The same cannot be said for HF-SLM method since the LOD values obtained for 
quinolones extracted from water matrices analysed by HPLC [79], were lower in most cases than the 
ones obtained in this study.  The LOQ values of the two methods differ for most analytes except for 
difloxacin, nalidixic acid and norfloxacin.  In terms of precision, HF-SLM method has been found to 
be more precise for all analytes since very low % RSD (CV) were obtained (i.e. 0.66 -14.4 %).  The 
precision for dSPE method was varying between analytes ranging from 1 - 25 %, with difloxacin going 
beyond the acceptable limit of ± 23%.  
  
Statistical comparison using a two – tailed test at 95 % confidence interval was carried out using the 
mean recoveries at MRL/action level obtained from both methods to evaluate if there is any significant 
difference between the two methods.  The obtained results show that there is a significant difference 
for ciprofloxacin, difloxacin and sarafloxacin because the calculated t-values are higher (11.0 – 26.7) 
than the t-critical values (4.30).  On the other hand the t-values obtained for enrofloxacin, danofloxacin, 
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nalidixic acid and norfloxacin are less than (0 - 3.89) the t-critical value showing that there is no 
significant difference between the two methods during extraction of these analytes.  The values are as 
shown in Table 4.9 using the student t-test at 95 % confidence interval [112]. 
 
Table 4.9: Comparison of HF - SLM with dSPE using student t-test for the mean recoveries of 
each quinolone analyte at MRL/action level (25 - 750 µg kg-1) (n = 21) 
 
 
4.7 Application of HF-SLM to real bovine kidney samples 
 
Some bovine kidney samples obtained from Botswana National abattoirs were analysed for quinolones 
using the optimized HF-SLM parameters.  Ten bovine kidney samples were homogenized and 
weighed.  Two samples were treated as quality control samples and spiked at MRL level.  Five 
milliliters of a mixture of 0.1% phosphoric acid: acetonitrile (30:70 v/v) was added to all samples 
followed by 10 mL of NaH2PO4 at pH 7 to extract the analytes.  The samples were applied to HF-SLM 
for further extraction and pre-concentration.  A matrix-matched calibration curve was used for 
Analyte Mean % recoveries 
HF-SLM 
Mean % recoveries 
dSPE 
Standard 
deviation 
t –value t-critical 
Ciprofloxacin 91 
106 
10.6 12.2 4.30 
Enrofloxacin 103 
103 
0 0 4.30 
Danofloxacin 89 
96 
4.95 3.89 4.30 
Difloxacin 100 
114 
9.90 11.0 4.30 
Nalidixic acid 104 
100 
2.83 1.68 4.30 
Norfloxacin 105 
101 
2.83 1.68 4.30 
Sarafloxacin 100 
110 
7.07 26.7 4.30 
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quantification of the analytes in the samples with the addition of internal standards to all samples 
including the calibration curve.  None of the analysed samples were positive for quinolones at 
detectable levels.  Figure 4.6 shows a chromatogram from a negative sample, showing only peaks for 
the internal standards. 
 
 
Figure 4.6 Chromatogram of extracted bovine kidney sample showing internal standards 
(enrofloxacin-d5, difloxacin-d3 and norfloxacin-d5) only.    
 
Figure 4.7a below shows a chromatogram from a spiked quality control sample obtained using the 
optimized HF-SLM method.  The obtained peaks in the chromatogram are not well resolved.  Figure 
4.7b to 4.7d shows the individual analytes from chromatogram 4.7a, which have been successfully 
extracted from the sample. The intensity of compounds obtained from HF-SLM extracted from spiked 
bovine kidney samples were lower for each analyte compared to those extracted with dSPE.  For 
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instance, the intensities for enrofloxacin are 3.8 x 103 for HF-SLM and 2.5 x 105 for dSPE, for 
norfloxacin the values are 3.0 x 103 for HF-SLM while for dSPE is 1.0 x 105 (Figure 4.7b).  HF-SLM 
is a delicate technique since the fibers used are very small and must be handled with care.  Possibility 
of loss of analyte during extraction is very high which could have lead to the lower intensities.  
 
Figure 4.7a: Chromatogram showing separation of quinolones extracted from a spiked bovine 
kidney using the optimised HF- SLM method.  A Phenomenex Kinetex 2.6 μm XB-C18 100 mm x 4.6 
mm, 100Å column was used.  Mobile phases A (0.1% formic in water) and B (methanol), at a flow 
rate of 0.4 mL min-1, injection volume of 20 µL and column temperature was optimized at 40 ̊C. 
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Figure 4.7b:  Extracted ion chromatograms of each analyte obtained from the total ion 
chromatogram in Figure 4.7a; showing retention times of each analyte. 
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Figure 4.7c:  Extracted ion chromatograms of each analyte obtained from the total ion 
chromatogram in Figure 4.7a; showing retention times of each analyte. 
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Figure 4.7d:  Extracted ion chromatograms of each analyte obtained from the total ion 
chromatogram in Figure 4.7a; showing retention times of each analyte. 
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CHAPTER 5: CONCLUSIONS 
 
A greener sample extraction, clean-up and pre-concentration method based on hollow fiber - supported 
liquid membrane (HF-SLM) was developed as an alternative for extraction of quinolone antibiotics 
(enrofloxacin, ciprofloxacin, danofloxacin, difloxacin, nalidixic acid, norfloxacin and sarafloxacin) in 
biological samples such as bovine kidney and analysed by LC-ESI-MS/MS.  The method was 
optimised and validated following the 2002/657/EC directive.  The optimized parameters were 
therefore; 0.1 % formic acid at pH 3 as the acceptor phase, triethylamine as the liquid membrane, 
NaH2PO4 at pH 7 as the donor phase and extraction time of 60 minutes.  The validated parameters 
under optimum conditions were linearity in the range of 0.9714 to 0.9975, LODs (3 to 39 µg kg-1), 
LOQs (10 to 130 µg kg-1), CCα (28 to 422 µg kg-1), and CCβ (29 to 454 µg kg-1).  The method was 
found to be reproducible with CVs ≤ 23%.  When applied to real bovine kidney samples obtained from 
local abattoirs the results showed that the analysed samples had non-detectable quinolone antibiotics 
levels based on the extraction method and detection technique used.  This implies that withdrawal 
periods are being complied with before animals are slaughtered.  Another sample preparation method 
employing dispersive solid phase extraction was also developed and validated for extraction of 
quinolones in bovine kidney.  Validated parameters such as linearity (12.5 to 750 µg kg-1), CCα (27 to 
429 µg kg-1), CCβ (30 to 464 µg kg-1) were obtained.  LOD and LOQs for dSPE also ranged between 
3 to 39 µg kg-1 and 10 to 130 µg kg-1 respectively but the values differ for some analytes. The two 
sample preparation methods were found to be comparable for some analytes (enrofloxacin, 
danofloxacin, norfloxacin and nalidixic acid) when statistically subjected to a t-test using recovery 
data, while there was a significant difference for some of the analytes such as ciprofloxacin, difloxacin 
and sarafloxacin.  From the discussion above, it can be concluded that hollow fiber –supported liquid 
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membrane can be used as an alternative method for extraction, clean-up and as a pre-concentration 
method for quinolones in bovine kidney.  
 
5.1 Limitations, challenges and future work  
 
It was discovered during the study when using the hollow fibers that they are very fragile to work with.  
Possibility of sample loss is very high and there is a need to handle them with care.  For future work, 
it would be a good research area to explore the use of an anion carrier to cater for extraction of acidic 
analytes like nalidixic acid which is different from other analytes to enhance its extraction.  There is 
also a need to analyse positive samples using HF-SLM to prove that it can be used as an alternative 
method to d-SPE.   
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